Suppr超能文献

抑制髓鞘碱性蛋白85 - 99表位与多发性硬化相关的HLA - DR2分子结合以及MBP特异性T细胞反应的合成肽。

Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.

作者信息

Fridkis-Hareli M, Stern J N, Fugger L, Strominger J L

机构信息

Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.

出版信息

Hum Immunol. 2001 Aug;62(8):753-63. doi: 10.1016/s0198-8859(01)00279-8.

Abstract

Copolymer 1 (Cop 1, poly [Y, E, A, K]) is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS), a disease that is linked to HLA-DR2 (DRB11501). In the present study various peptides, synthesized according to the binding motifs for both the immunodominant epitope of myelin basic protein (MBP) 85-99, a candidate autoantigen in MS, and Cop 1, differentially inhibited binding of these antigens to disease-associated HLA-DR2 (DRB11501) molecules. In particular, two peptides with residue K at position P-1, as referred to MBP 85-99, inhibited effectively the binding of both biotinylated MBP 85-99 and Cop 1 to HLA-DR2 molecules as well as IL-2 production by two MBP-specific HLA-DR2-restricted T-cell clones. These findings suggest the possible utility of these compounds or their more stable derivatives in treatment of MS.

摘要

共聚体1(Cop 1,聚[Y,E,A,K])是一种随机合成的氨基酸共聚体,对复发型多发性硬化症(MS)有效,该疾病与HLA - DR2(DRB11501)相关。在本研究中,根据髓鞘碱性蛋白(MBP)85 - 99(MS中的一种候选自身抗原)的免疫显性表位以及Cop 1的结合基序合成的各种肽,差异性地抑制了这些抗原与疾病相关的HLA - DR2(DRB11501)分子的结合。特别是,相对于MBP 85 - 99在P - 1位置带有残基K的两种肽,有效抑制了生物素化的MBP 85 - 99和Cop 1与HLA - DR2分子的结合,以及两个MBP特异性HLA - DR2限制性T细胞克隆产生白细胞介素-2。这些发现表明这些化合物或其更稳定的衍生物在治疗MS方面可能具有实用性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验